BioMarin Pharmaceutical Inc.

712 articles with BioMarin Pharmaceutical Inc.

• BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference

  6/15/2021

   BioMarin Pharmaceutical Inc. today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on June 16, 2021 at 3:30pm ET .

• BioMarin to Participate in Two Upcoming Virtual Investor Conferences - May 27, 2021

  5/27/2021

  BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

• BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

  5/19/2021

  All Study Participants in 6e13 vg/kg and 4e13 vg/kg Dose Cohorts Remain off Factor VIII Prophylactic Therapy 95% Reductions in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annualized Factor VIII Usage Through Year 5 in 6e13 vg/kg Dose Cohort

• BioMarin to Participate in Two Upcoming Virtual Investor Conferences - May 18, 2021

  5/18/2021

  BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

• BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

  5/12/2021

  BioMarin today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14. 

• BioMarin to Participate in Two Upcoming Virtual Investor Conferences - May 03, 2021

  5/3/2021

  BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

• BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates

  4/29/2021

  FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results

• BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice

  4/15/2021

  Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia

• BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET

  4/13/2021

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29 , at 4:30 p.m. ET to discuss first quarter 2021 financial results and provide a general business update.

• BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide

  3/20/2021

  BioMarin Pharmaceutical Inc. announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society's Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Parkville, Victoria.

• BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

  3/8/2021

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.

• BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

  3/3/2021

  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans

• BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates

  2/25/2021

  BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter and full year ended December 31, 2020.

• BioMarin to Participate in Four Upcoming Virtual Investor Conferences - Feb 24, 2021

  2/24/2021

  BioMarin Pharmaceutical Inc. announced that management will participate in four upcoming virtual conferences.

• BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors

  2/18/2021

  BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to its Board of Directors.  

• BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index

  1/28/2021

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the Company received the top score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality

• BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET

  1/26/2021

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25 , at 4:30 p.m. ET to discuss fourth quarter and full year 2020 financial results and provide a general business update.

• BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

  1/10/2021

  Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value <0.0001) Demonstrating Superiority to Factor VIII Prophylaxis, and Reduced Mean Annualized Factor VIII Infusion Rate by 99% (p-value <0.0001)

• BioMarin to Participate in Two Upcoming Virtual Investor Conferences - Jan 05, 2021

  1/5/2021

  BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

• BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

  12/21/2020

  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment.